Baird Maintains an 'Outperform' on Regeneron Pharma (REGN); Still Taking Share AND Growing the Branded Market

Baird maintains an 'Outperform' on Regeneron Pharma (NASDAQ: REGN), new price target of $130.00.

Analyst, Christopher Raymond, said, "Ahead of tomorrow's Q112 earnings report, we highlight herein fresh survey data indicating Eylea's launch remains on an impressive trajectory. With all uptake metrics directionally robust, we remain comfortable with our above-consensus estimate and would not be shocked to see upside even to our number. Accordingly, we think Q112 earnings will be a positive event for the stock. We are now buyers into the $130 range."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $122.54 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
• Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities